NCT07039474Recruiting
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 26 May 2025
- Start date
- 8 Sept 2026
- Primary completion date
- 1 Dec 2028
- Lead sponsor
- Peking University First Hospital
- NCT number
- NCT07039474
What you commit to
- Study type: Observational
- Planned participants: 120
- From 8 Sept 2026 to the primary completion date, 1 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving radiotherapy or interventional therapy during the immunotherapy.
- 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.
Other illness
- Combined with other malignant tumor.
- Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy.
- Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency.
Other
- Women in the preconception period, pregnancy, or lactation period.
Who the study is looking for
- Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team.
- Subjects didn't receive previous immunotherapy.
- There exists at least one measurable target lesion according to the RECIST 1.1.
- ECOG performance status≤2.
- The expected survival time is ≥6 months.
- Effective contraceptive measures will be adopted during the study period and within 6 months after the study.
- Willing and able to fully understand and sign the informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.